Biohaven Ltd. (BHVN)
15.29
+0.81
(+5.59%)
USD |
NYSE |
Nov 09, 11:58
Biohaven Total Assets (Quarterly) : 263.68M for Sept. 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 263.68M |
| June 30, 2026 | 370.74M |
| March 31, 2026 | 466.41M |
| December 31, 2025 | 451.45M |
| September 30, 2025 | 409.12M |
| June 30, 2025 | 550.42M |
| March 31, 2025 | 458.95M |
| December 31, 2024 | 615.11M |
| September 30, 2024 | 510.52M |
| Date | Value |
|---|---|
| June 30, 2024 | 582.64M |
| March 31, 2024 | 418.53M |
| December 31, 2023 | 513.21M |
| September 30, 2023 | 382.74M |
| June 30, 2023 | 506.74M |
| March 31, 2023 | 618.52M |
| December 31, 2022 | 661.78M |
| September 30, 2022 | 135.65M |
| June 30, 2022 | 98.22M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| NovelStem International Corp. | 0.0647M |
| Brainstorm Cell Therapeutics, Inc. | 0.788M |
| Summit Therapeutics, Inc. | 692.85M |
| Kezar Life Sciences, Inc. | 68.00M |
| Protara Therapeutics, Inc. | 156.54M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 361.92M |
| Shareholders Equity (Quarterly) | -98.25M |
| Debt to Equity Ratio | -3.058 |
| Current Ratio | 3.051 |
| Net Debt Paydown Yield | -0.09% |